×
2seventy Bio EBIT 2020-2024 | TSVT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
2seventy Bio ebit from 2020 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
2seventy Bio EBIT 2020-2024 | TSVT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
2seventy Bio ebit from 2020 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$173B
Vertex Pharmaceuticals (VRTX)
$129.2B
Bristol Myers Squibb (BMY)
$121.3B
Gilead Sciences (GILD)
$120.8B
CSL (CSLLY)
$91.5B
Regeneron Pharmaceuticals (REGN)
$90.7B
GSK (GSK)
$75.3B
Alnylam Pharmaceuticals (ALNY)
$36.1B
Argenex SE (ARGX)
$35.2B
BioNTech SE (BNTX)
$26.1B
Biogen (BIIB)
$25.1B
Illumina (ILMN)
$24B
BeiGene (BGNE)
$20B
Moderna (MRNA)
$16.5B
Incyte (INCY)
$15.7B
Genmab (GMAB)
$15.4B
Vaxcyte (PCVX)
$12.9B
Insmed (INSM)
$12.8B
BioMarin Pharmaceutical (BMRN)
$12.6B
Bio-Techne Corp (TECH)
$11.9B
Sarepta Therapeutics (SRPT)
$11.3B
Exelixis (EXEL)
$10.3B
Revolution Medicines (RVMD)
$10.2B
QIAGEN (QGEN)
$10.1B
Intra-Cellular Therapies (ITCI)
$9.7B
Exact Sciences (EXAS)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$7.8B
Ascendis Pharma (ASND)
$7.8B